Published in Hepatitis Weekly, February 11th, 2008
"16 outpatient clinics. 135 treatment-naive, HBeAg-positive adults with chronic hepatitis B. Patients were randomly assigned in a 1: 1:1 ratio to 52 weeks of telbivudine (group A) or adefovir (group B), or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly